SubscribeBioWorld - Monday, May 11, 2020Home Xenikos eyes Q1 2018 start for pivotal trial of T-Guard in acute GVHDLooking to read the full article? Subscribe to BioWorld.Xenikos eyes Q1 2018 start for pivotal trial of T-Guard in acute GVHD December 11, 2017 By Cormac Sheridan No CommentsDUBLIN – Xenikos BV aims to move its T-Guard cocktail of two antibody-drug conjugates into a pivotal phase III trial in acute graft-vs.-host disease (aGVHD) early next year, on the back of data from an open-label phase I/II trial, in which 12 of 18 treated patients (67 percent) remained alive at six months.BioWorld